BrainsWay Ltd. Sponsored ADR
BrainsWay Ltd. Sponsored ADR is a medical technology company focused on non-invasive neurostimulation treatments for brain and mental health disorders. BrainsWay develops and commercializes its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) systems, which use magnetic pulses to stimulate targeted brain regions and support treatment for conditions such as major depressive disorder and obsessive-compulsive disorder. The company’s products are used in psychiatric and clinical settings, serving physicians, hospitals, and medical centers that incorporate device-based therapies into patient care. BrainsWay also addresses broader neurological and mental health applications through its commercial treatment platforms and related services. Headquartered in Jerusalem, Israel, BrainsWay operates as a specialized healthcare equipment provider with a focus on advanced brain stimulation technologies and the clinical markets that use them.
$11.44
-$0.38 (-3.21%)
EOD Oct 16, 2026
Operating margin is thin at 8.28%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 27.3% YoY with margins expanding 4.9pp.
At 48x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
47.7x earnings, 78.4x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$61M
▲ +27.3% YoY
Net Income (TTM)
$9M
▲ +161.3% YoY
Op. Margin
12.46%
▲ +4.9pp YoY
ROIC
5.78%
▲ +3.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$6M
▲ +150.2% YoY
Op. Cash Flow (TTM)
$8M
▲ +162.6% YoY
Net Debt
-$62M
Net Cash Position
Cash & Equiv.
$69M
3Y CAGR: +24.3%
Continue Research
Is BrainsWay Ltd. Sponsored ADR (BWAY) overvalued?
At a P/E of 47.7 and a price-to-free-cash-flow of 78.4, BrainsWay Ltd. Sponsored ADR (BWAY) trades above a two-stage DCF intrinsic value of about $4.14 per share, so at $11.44 the stock looks overvalued (63.8% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, BrainsWay Ltd. Sponsored ADR scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is BrainsWay Ltd. Sponsored ADR's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $4.14 per share for BWAY, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $3.10. At today's $11.44, that puts the stock about 63.8% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is BrainsWay Ltd. Sponsored ADR a high-quality business?+
BrainsWay Ltd. Sponsored ADR scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 12.5% operating margin and a 5.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is BrainsWay Ltd. Sponsored ADR a good stock to buy right now?+
That depends on valuation and quality together, not either alone. BWAY currently trades above its estimated intrinsic value and scores 50/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Medical Devices
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.